IP Library Granted Patent US 6,933,132
Granted Patent B1
US 6,933,132 · App. 09/787,097 · Granted Aug 23, 2005

Regulation of immune responses by attractin

Assignee: Dana-Farber Cancer Institute Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,933,132
App. No.
09/787,097
Granted
Aug 23, 2005
Kind
B1
Abstract

The invention features attracting polypeptides and nucleic acids encoding them. The attractin polypeptides are useful for enhancing immune responses.

Claims (63)

1. An isolated DNA comprising a nucleic acid sequence that encodes an amino acid sequence comprising SEQ ID NO:12.

2. An isolated DNA comprising a nucleic acid sequence consisting of SEQ ID NO:13.

3. An isolated nucleic acid comprising a nucleic acid sequence encoding a fusion protein, the fusion protein consisting of:

(a) SEQ ID NO:12 or an antigenic fragment of SEQ ID NO:12, wherein the antigenic fragment is at least five amino acids long; and

(b) a heterologous polypeptide.

4. A vector comprising the isolated DNA of claim 1 .

5. The vector of claim 4 , wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of said nucleic acid sequence in a cell.

6. An isolated cell comprising the vector of claim 5 .

7. A method of producing a polypeptide, the method comprising culturing the cell of claim 6 and purifying the polypeptide from the cell.

8. A vector comprising the isolated nucleic acid of claim 3 .

9. The vector of claim 8 , wherein the nucleic acid is operably linked to a regulatory element that allows expression of said nucleic acid in a cell.

10. An isolated cell comprising the vector of claim 8 .

11. A method of producing a fusion protein, the method comprising culturing the cell of claim 10 and purifying the fusion protein from the cell.

12. An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6× SSC at 30° C., followed by one or more washes in 0.2× SSC and 0.1% sodium dodecyl sulfate (SDS) at 50° C. to 65° C., wherein the nucleic acid sequence consists of SEQ ID NO:1; or

(b) the complement of the nucleic acid sequence.

13. An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6× SSC at 30° C., followed by one or more washes in 0.2× SSC and 0.1% sodium dodecyl sulfate (SDS) at 50° C. to 65° C., wherein the nucleic acid sequence consists of SEQ ID NO:11; or

(b) the complement of the nucleic acid sequence.

14. An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6× SSC at 30° C., followed by one or more washes in 0.2× SSC and 0.1% sodium dodecyl sulfate (SDS) at 50° C. to 65° C., wherein the nucleic acid sequence consists of SEQ ID NQ: 9; or

(b) the complement of the nucleic acid sequence.

15. The isolated nucleic acid of claim 3 , wherein the heterologous polypeptide comprises a signal peptide, a reporter polypeptide, or an immunoglobulin constant region.

16. An isolated DNA consisting of a sequence encoding an antigenic fragment of SEQ ID NO:12, wherein the antigenic fragment is at least five amino acids long.

17. An isolated DNA comprising a nucleic acid sequence that encodes a polypeptide consisting of the following segments in contiguous order, starting from the N-terminus of the amino acid sequence:

(a) amino acids 1-30 of SEQ ID NO:12;

(b) amino acids 31-104 of SEQ ID NO:12;

(c) amino acids 105-1267 of SEQ ID NO:12; and

(d) amino acids 1268-1429 of SEQ ID NO:12 or amino acids 1194-1999 of SO ID NO:2,

wherein the polypeptide enhances spreading of a macrophage or a monocyte.

18. The DNA of claim 17 , wherein the polypeptide comprises amino acids 1194-1999 of SEQ ID NO:2.

19. The DNA of claim 17 , wherein the polypeptide comprises amino acids 1268-1429 of SEQ ID NO:12.

20. A vector comprising the isolated DNA of claim 16 .

21. The vector of claim 20 , wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

22. An isolated cell comprising the vector of claim 21 .

23. A method of producing a polypeptide, the method comprising culturing the cell of claim 22 and purifying the polypeptide from the cell.

24. A vector comprising the isolated DNA of claim 17 .

25. The vector of claim 24 , wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

26. An isolated cell comprising the vector of claim 25 .

27. A method of producing a polypeptide, the method comprising culturing the cell of claim 26 and purifying the polypeptide from the cell.

28. The nucleic acid of claim 3 , wherein a nucleotide sequence encoding the antigenic fragment is at least 50 NUCLEOTIDES long.

29. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 100 nucleotides long.

30. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 300 nucleotides long.

31. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 800 nucleotides long.

32. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 1,500 nucleotides long.

33. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 3,000 nucleotides long.

34. The nucleic acid of claim 28 , wherein the nucleotide sequence is at least 4,000 nucleotides long.

35. The DNA of claim 16 , wherein the a nucleotide sequence encoding the antigenic fragment is at least 50 nucleotides long.

36. The DNA of claim 35 , wherein the nucleotide sequence is at least 100 nucleotides long.

37. The DNA of claim 35 , wherein the nucleotide sequence is at least 300 nucleotides long.

38. The DNA of claim 35 , wherein the nucleotide sequence is at least 800 nucleotides long.

39. The DNA of claim 35 , wherein the nucleotide sequence is at least 1,500 nucleotides long.

40. The DNA of claim 35 , wherein the nucleotide sequence is at least 3,000 nucleotides long.

41. The DNA of claim 35 , wherein the nucleotide sequence is at least 4,000 nucleotides long.

42. An isolated DNA comprising a nucleic acid sequence that encodes a polypeptide consisting of the following segments in contiguous order, starting from the N-terminus of the amino acid sequence:

(a) amino acids 1-30 of SEQ ID NO:12;

(b) amino acids 105-1267 of SEQ ID NO:12; and

(c) amino acids 1268-1429 of SEQ ID NO:12, or amino acids 1194-1999 of SEO ID NO: 2,

wherein the polypeptide enhances spreading of a macrophage or a monocyte.

43. A vector comprising the isolated DNA of claim 42 .

44. Thc vector of claim 43 , wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

45. An isolated cell comprising the vector of claim 44 .

46. A method of producing a polypeptide, the method comprising culturing the cell of claim 45 and purifying the polypeptide from the cell.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 29, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040697/0711 →
CONFIRMATORY LICENSE Recorded Sep 20, 2016
From: DANA-FARBER CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR
Reel/Frame 039801/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2001
From: DUKE-COHAN, JONATHAN S.; SCHLOSSMAN, STUART F.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 011961/0109 →
Continuity (1)
Provisional Application 6010013700 · Sep 14, 1998